ASPHO Conference | Conference

Expert Explains State of TKI Treatment in Pediatric CML

May 10th 2018

Discontinuation of tyrosine kinase inhibitor treatment may be a possibility for children with chronic myeloid leukemia and, because they could be on-treatment for decades, treatment-free remission is even more important for pediatric patients than for adults.

Eltrombopag Improves Platelet Count in Pediatric HIV

May 8th 2018

Eltrombopag (Promacta) boosted the platelet count in a 13-year-old boy with HIV-associated thrombocytopenia, according to case study results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference.

Dr. Engel on the Use of Eltrombopag in HIV-Related Thrombocytopenia

May 5th 2018

Elissa Engel, MD, pediatric resident, University of South Florida, discusses the successful use of eltrombopag (Promacta) in a pediatric patient with HIV-related thrombocytopenia.

COG to Assess Targeted Therapies in a Variety of NHL Clinical Trials

May 5th 2018

The Children's Oncology Group is currently involved in 5 studies exploring targeted therapies in non-Hodgkin lymphoma (NHL) that could eventually change the face of pediatric NHL treatment.

Tisagenlecleucel Safety, Efficacy Promising in Pediatric Down Syndrome and ALL

May 4th 2018

A first-time study of chimeric antigen receptor T-cell therapy in youths with Down syndrome-associated relapsed/refractory (r/r) acute lymphoblastic leukemia produced high remission rates and toxicity results that were similar to those observed in patients with r/r ALL.

Tazemetostat Shows Antitumor Activity in INI1-Negative Pediatric Tumors

May 4th 2018

Tazemetostat demonstrated promising antitumor activity in pediatric patients with INI1-negative solid tumors.

Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors

May 4th 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of Pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children with INI1-negative tumors.

Selective T-Cell Depletion Improves Engraftment, Reduces GVHD in Pediatric/AYA Leukemia

May 4th 2018

Eliminating T cells carrying alpha and beta chains of the T-cell receptor reduced the risk for graft-versus-host-disease while producing "excellent" engraftment kinetics for young patients with acute leukemia who underwent hematopoietic stem cell transplant.

2B8T2M Enhances exPBNK Expression, in Vitro Cytotoxicity in Rituximab-Sensitive/Resistant Burkitt Lymphoma

May 3rd 2018

2B8T2M, a fusion of the IL-15 superantagonist ALT-803, and 4 single-chains of rituximab (Rituxan) significantly boosted the cytotoxicity of expanded peripheral blood natural killer cells against Burkitt lymphoma cells in in vitro testing.

Dr. Bailey Discusses Key Molecular Pathways in Bone Sarcoma

May 3rd 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses key molecular pathways in pediatric bone sarcoma.

Dr. Crompton Discusses Liquid Biopsies in Pediatric Sarcoma

May 3rd 2018

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the utilization of liquid biopsies in pediatric patients with sarcoma.

CAR T-Cell Therapy May Serve as a Bridge to HCT in ALL

May 3rd 2018

CAR T-cell therapy can induce next generation sequencing negativity in patients with relapsed/refractory acute lymphoblastic leukemia, suggesting a "synergistic" relationship with hematopoietic cell transplant.